Furthermore, there was a significant increase in serum AST levels in NASH-HCC patients by 151% compared to NASH patients, despite being suggestive of liver damage but not specific to hepatic carcinogenesis. Here, GOT1 is linked to metabolic dysfunction-associated steatohepatitis.